Future Market Insights.png
Automobile Industry’s Demand for Efficiency Boosting the Heat Shield Market is anticipated to have reached a value of US$ 8.9 Billion by 2034 | Future Market Insights NEWARK, Del, March 28, 2024 (GLOBE NEWSWIRE) -- The global heat shield market is expected to be valued at US$ 5.0 billion in 2024. The progress of the market is projected to be sturdy over the...
Lightweight Automotive Materials Market Races Ahead, Projected to Reach USD 112.50 Billion by 2030, Report by Persistence Market Research
January 15, 2024 07:30 ET | Persistence Market Research
New York, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Market Overview:The lightweight automotive materials market encompasses various product types utilized to reduce vehicle weight and improve fuel...
Ryzen_2
AMD Reveals Next-Gen Desktop Processors for Extreme PC Gaming and Creator Performance
January 08, 2024 10:30 ET | Advanced Micro Devices, Inc.
— AMD Ryzen™ 8000G Series desktop processors bring immense performance for gamers and creators and unlocks new personal AI experiences with Ryzen AI — — AMD bolsters desktop portfolio and...
Unknown.png
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
January 04, 2024 17:25 ET | Gradalis, Inc.
GRAD1405 uses Gradalis’ breakthrough gene silencing bi-shRNAi technology to specifically reduce the expression of certain mutated KRAS genesExisting therapies have experienced rapid drug resistance...
Unknown.png
Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
December 05, 2023 08:00 ET | Gradalis, Inc.
Emerging research shows that targeting initial mutations expressed on a tumor cell surface, called clonal mutations, is critical in achieving a durable clinical benefitFor example, lung cancer...
Unknown.png
Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas
November 16, 2023 15:12 ET | Gradalis, Inc.
DALLAS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a leader in the development of personalized anti-cancer cellular therapies for patients with solid tumors, announced today that it has been...
Unknown.png
Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer on October 25, 2023
October 18, 2023 08:00 ET | Gradalis, Inc.
DALLAS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer...
Unknown.png
Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
September 28, 2023 08:00 ET | Gradalis, Inc.
Evidence from multiple researchers supports Vigil enhancement of clonal neoantigen effector cell response and correlation to relapse free survival and overall survival benefit Targeting clonal...
Unknown.png
Gradalis to Participate in the Cantor Global Healthcare Conference
September 21, 2023 08:30 ET | Gradalis, Inc.
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, clinical stage biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian and...
Unknown.png
Gradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil Platform
June 06, 2023 16:05 ET | Gradalis, Inc.
Technology leverages new coating process to create 3D scaffold matrix that is designed to mimic the tumor microenvironment and enable large scale tumor cell expansionDemonstrated successful increase...